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Cancer is a leading cause of death in China with an estima-
tion of nearly 2 million deaths every year (Chen and Fu, 
2011b). Matter of a public health importance in China and 
worldwide, the scientific community is still facing many 
obstacles to eradicate cancer: complexity of a mul-
ti-factorial disease with organ-based specificities, high fail-
ure rate of many anti-cancer drugs in clinical trials, lack of 
understanding of the cancer genesis factors... Among all the 
possibility for new therapies, what should be the next trends 
for cancer treatment? Dr. Yixin Zeng, president of 
SYSUCC, emphasized that molecular typing and personal-
ized therapy is the future direction of modern medicine, and 
may eventually lead to a cure for cancer. Indeed, the field of 
oncology is moving toward the development of individual-
ized treatment based on tumor molecular profiling. 
Sun Yat-sen University Cancer Center (SYSUCC) is the 
largest integrated center in southern China for cancer-       
related care, education, research, and prevention. In addition 
with a comprehensive range of health-care services for can-
cer diagnosis and treatment (capacity over 1000 beds), 
SYSUCC has the necessary multi-disciplinary platform to 
conduct translational research with a SFDA accredited 
Clinical Trial Center, the State Key Laboratory of Oncology 
in South China and a tumor biobank.  
As mentioned by Minister Zhu Chen and Dr. Guangbiao 
Zhou in a previous issue of Science China, translational 
medicine is a people oriented practice (Chen et al., 2011b), 
defined as a bi-directional science aiming either to translate 
basic science discoveries into clinical applications (often 
referred as bench to bedside) or to convert clinical observa-
tions into mechanism studies (bedside to bench). In this 
review, we propose to summarize all translational studies 
from SYSUCC that promises to benefit patients. 
LARGE PANEL OF TRANSLATIONAL  
STUDIES ON NASOPHARYNGEAL  
CARCINOMA  
Nasopharyngeal carcinoma, a challenging disease 
Nasopharyngeal carcinoma (NPC) is a squamous cell car-
cinoma originating from the epithelial cell of the nasophar-
ynx. NPC has a very unbalanced epidemiologic repartition; 
although very frequent in South China and Southeast Asia, 
where its incidence can reach 20–50 per 100000 in high 
endemic region, it is quite rare among the caucasian popula-
tion (less than 1 per 100000 persons) (Lu et al., 2010; Cao 
et al., 2011; Adham et al., 2012; Kataki et al., 2011). This 
disease is thus extensively researched in SYSUCC, where 
every year about 2500 new NPC patients are treated. 
NPC is a highly malignant cancer that often invades adja-
cent regions and metastasizes to regional lymph nodes and 
distant organs. The overall five-year survival rate of NPC is 
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around 60%, whereas the stage-specific five-year survival 
rates range from 88% at the early stage down to 28% at the 
advanced stage. Because symptoms related to NPC in the 
early stage are usually nonspecific, 80% of NPC patients have 
developed a late-stage tumor by the time of diagnosis. There-
fore, it is important to acquire a basic understanding of the un-
derlying genetic and molecular mechanisms of NPC’s patho-
genesis to explore the possible high-risk factors and identify 
the markers for susceptibility and early diagnosis of NPC.  
Identification of genetic susceptibility and development of 
risk prediction model for nasopharyngeal carcinoma 
The involvement of genetic susceptibility in the etiology of 
NPC provides a way toward NPC risk prediction (Simons, 
2011; Shugart et al., 2011). Over the last decade, Dr. Yixin 
Zeng (president of SYSUCC) and his team have been 
working on the identification of genetic lesions that con-
tribute to the development of NPC. From studies of 
high-risk NPC families, Dr. Zeng’s team discovered a sus-
ceptibility locus in the 14.21-cM region of 4p15.1-q12 that 
was related to familial NPC (Feng et al., 2002). Moreover, 
based on a large-scale genome-wide analysis study, they 
have recently identified three novel loci for sporadic NPC, 
including MECOM on chromosome 3, CDKN2A/2B on 
chromosome 9, and TNFRSF19 on chromosome 13 (Bei et 
al., 2010). In addition, they found that DNA repair gene 
variants were associated with the risk of NPC in the Can-
tonese population of southern China (Qin et al., 2011). The 
identification of genetic risk factors for NPC is significant 
in developing an NPC risk prediction model and subsequent 
screening of the high-risk population to improve early di-
agnosis of NPC patients.  
To establish an NPC risk prediction model, Dr. Zeng’s 
ongoing research is separated into two parts: (i) identifying 
other genetic lesions that might lead to NPC (which will 
provide information relating to the genotype) and determin-
ing the sequence information from large samples of NPC 
patients and controls; and (ii) exploring the contribution of 
environmental factors, such as alcohol consumption and 
smoking as well as infection by Epstein-Barr virus, and the 
interaction of these factors with genetic lesions.  
Using chip technology, the presence of genetic risk vari-
ants for one individual can be determined, and this simulta-
neously allows the detection of any genetic lesions that may 
be present. The genetic information can then be fed into a 
risk prediction model together with data relating to envi-
ronmental risk exposure and virus infection; the result is a 
score that indicates an individual’s risk of developing NPC. 
A person with a high risk score can then be advised to take 
further medical examination. Therefore, the accuracy of the 
prediction model that Dr. Zeng’s team is currently working 
on will help people become more aware of the risk of NPC 
and will also increase the chances of early diagnosis. 
Biomarkers and nasopharyngeal carcinoma 
prognosis 
There is a pressing need to expand our knowledge about 
cancer biomarkers and develop a rapid, effective molecular 
classification platform to help diagnose NPC, identify the 
adapted treatment and predict clinical outcome. From the 
general opinion in SYSUCC, the current TNM staging sys-
tem of NPC should be refined to have a better correlation 
between each stage and its associated prognosis. With the 
recent advances in molecular biology, scientists hope to find 
new molecular markers that can complement the existing 
staging system and improve treatment strategy for NPC. 
Scientists in SYSUC are investigating this issue from 
different approaches and discovered several potential prog-
nostic biomarkers for NPC. For example, Dr. Jianyong Shao 
and his team (Department of Molecular Diagnostics, SKL 
of Oncology in South China) developed a bioinformatics 
method to construct a prognosis classification system for 
NPC, called the NPC-support vector machine (SVM) classi-
fier (Wang et al., 2011). With eight parameters (gender and 
protein level expression of seven genes), the classifier can 
separate NPC patients into two categories: high and low 
risks groups based on their five-year disease specific sur-
vival. This model aims to be applied in clinical practice and 
enhance individualized management of this disease.  
Another study led by Dr. Jun Ma emphasizes the im-
portant role of MicroRNAs (miRNAs) for NPC prognosis. 
Indeed, miRNAs, a family of small non-coding RNAs, are 
known to be deregulated in many cancers and to be in-
volved in the pathogenesis of NPC. Based on this, Dr. Jun 
Ma and his team proposed a five-miRNA signature, predic-
tive of patient survival, which can potentially identify can-
didates for aggressive therapy (Liu et al., 2012). 
NPC is known to be related to Epstein-Barr virus (EBV) 
infection and EBV-specific antibodies are routinely used for 
NPC diagnosis (Dardari et al., 2001) but not for prognosis. 
In Dr. Qiang Liu’s study, researchers found that serological 
anti-enzyme rate (AER) of EBV DNase-specific neutraliz-
ing antibody could be used as an independent NPC prog-
nostic marker complementing TNM staging (Xu et al., 
2010). 
ANTICANCER DRUG DEVELOPMENT  
Molecular targeted therapy 
In anti-cancer drug discovery, the model has shifted from 
non-specific cytotoxic chemotherapeutics to molecular tar-
geted agents. Thanks to the progress of molecular biology, 
scientists are able to find small molecules that interfere with 
specific molecular pathways in cancer cells development to 
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inhibit their progression (Liu et al., 2011). Studies conduct-
ed at SYSUCC aim to identify and evaluate potential targets 
for treatment, especially for NPC and liver cancer.  
Researchers have discovered that Met overexpression 
and PI3KCA mutation are common in NPC, which makes 
the PI3K/AKT pathway a potential target for treatment. For 
example, a recent study showed that DC120, a 2-pyrimidyl- 
5-amidothiazole compound, was inhibiting proliferation in 
human nasopharyngeal carcinoma and breast cancer cells 
(Deng et al., 2012). Interestingly, several other compounds 
targeting PI3K/AKT pathway were developed from natural 
products used in traditional Chinese medicine and showed 
in-vitro and in-vivo potent anti-cancer activities. For exam-
ple, excisaninA from Isodon specifically induces tumor cell 
apoptosis and reduces tumor growth for hepatocellular car-
cinoma and breast cancer (Deng et al., 2009), SYUNZ-16 
from Arnebia euchroma roots inhibits proliferation of lung 
adenocarcinoma and hepatocellular carcinoma (Deng et al., 
2010) or emodin AMAD (azide methyl anthraquinone de-
rivative) extracted from nature’s giant knotweed rhizome 
showing promises for the treatment of Her2/neu-overex- 
pressing cancers (Yan et al., 2011). 
From a collaborative work with Sun Yat-sen University, 
School of Pharmaceutical Science, it was found that quino-
line derivatives interacted preferentially with intramolecular 
G-quadruplex structures and were novel potent telomerase 
inhibitors (Zhou et al., 2006). 
For many years, Dr. Liwu Fu and his group have been 
working on reversing multidrug resistance (MDR), a mech-
anism by which cancer cells tend to become resistant to 
chemotherapy. Tyrosine-kinase inhibitors are a hot area in 
anti-cancer drug development because they inhibit the func-
tion of ATP binding cassette transporters and restore the 
sensitivity of MDR cells (Chen et al., 2011a). For example, 
FG020326, a newly synthesized triaryl-substituted imidaz-
ole derivative, reversed MDR in vitro and in vivo (Dai et al., 
2008a). Uncovering the anti-cancer properties of small 
molecules Apatinib and Lapatinib in combination with 
conventional chemotherapy is also an active and promising 
area of research at SYSUCC (Mi et al., 2010; Dai et al., 
2008b)  
Innovative antiangiogenesis agent against solid tumors 
–– adenovirus carrying human endostatin (E10A) 
Despite recent progress in the management of cancer, the 
majority of advanced metastatic solid tumors are still not 
curable using current treatment modalities. There are many 
reasons for the inability to eradicate malignant neoplasms 
using conventional cytotoxic drugs. Chemotherapy is not 
specific for cancer: it targets all rapidly proliferating cells 
by inhibiting DNA synthesis or interfering with different 
pathways of cell division and metabolism. Chemotherapy is 
frequently associated with significant dose-limiting side 
effects related to toxicity to normally dividing cells in the 
bone marrow, skin, and gastrointestinal mucosa. Develop-
ing a targeted anticancer drug is clearly beneficial to pa-
tients. Angiogenesis plays a critical role in cancer develop-
ment and metastasis, and endostatin is one of the most ef-
fective inhibitors of angiogenesis. 
An adenovirus-carrying endostatin gene product (E10A) 
has been developed at SYSUCC by Dr. Wenlin Huang, in 
conjunction with Guangzhou Doublle Bio-products Co., Ltd. 
(Guangzhou, China) for advanced head and neck tumors (Li 
et al., 2008; Lin et al., 2007; Huang et al., 2007). E10A, an 
adenovirus-carrying endostatin gene, can dramatically in-
crease the tumor drug concentration in metronomic chemo-
therapy with low-dose cisplatin in a xenograft mouse model 
for head and neck squamous cell carcinoma. The formula-
tion of the E10A product with a PEGylated and lyophilized 
preparation can be given as a venous injection. To investi-
gate the effect of this new targeted drug, a multicenter phase 
II clinical trial has been conducted, and the results with 
progress-free survival rate are promising. The phase III 
clinical trial of E10A is on-going this year. Intellectual 
properties related to the formulation are covered by a Chi-
nese patent, which has won the 12th China Patent Gold 
Award for innovative patents. 
ESSENTIAL ROLE OF THE ANIMAL 
FACILITY FOR TRANSLATIONAL STUDIES 
Animal models play a critical role to translate basic research 
discovery into clinical applications and, vice versa. In can-
cer research, animal models have been widely used for mul-
tiple purposes, including etiology studies, drug screening, 
cancer progression (tumorigenesis, metastasis, tumor angi-
ogenesis, cachexia, etc.) and cancer prevention studies. The 
advantage of disease model based on animals over cell lines 
is that it mimics better human response to therapeutic in 
terms of physiological environment, genetic and morpho-
logic features. 
Aurora-A (Aur-A), a kinase involved in chromosome 
segregation during mitosis, has been reported to be a poten-
tial target for cancer therapy (Gautschi et al., 2008). Several 
studies, led by Dr. Qiang Liu, already proved the important 
role of Aur-A in diverse tumor characteristics in vitro. For 
example, Aur-A increases migration and reduces radiosen-
sitivity in laryngeal cancer cells (Guan et al., 2007), and it 
also promotes epithelial-mesenchymal transition and inva-
siveness in nasopharyngeal carcinoma (Wan et al., 2008). So 
far, nude mice studies have shown that Aur-A promoted 
breast cancer migration and metastasis through the Col-
lin-F-actin pathway (Wang et al., 2010). In order to test the 
efficiency of Aur-A targeted therapy, further in vivo studies 
are necessary, so, in that perspective, SYSUCC scientists are 
currently working on generating Aur-A inducible transgenic 
mice. 
Other studies aim to identify the role of signal transducer 
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and activator of transcription-5 (STAT5) in leukemia using 
conditional knockout mouse. Leukemia phenotype can be 
induced by collecting bone marrow cells after Poly-IC 
treatment and infecting the cells with BCR/Abl or Flt3 virus. 
By analyzing bone marrow cells from wild type mice, sci-
entists plan to have a better understanding of the STAT5 
pathway involved in Leukemia development and thus find 
inhibitors for targeted therapy. 
BIOBANK AS THE BASIS FOR  
TRANSLATIONAL STUDIES 
Biobanks are essential for translational medical studies and 
are a valuable resource for both basic and clinical research. 
As one of the earliest (2001) and largest bio-repositories in 
China, the tumor biobank has become an important part of 
SYSUCC and the SKL of oncology in South China. Fol-
lowing the heterogeneity of cancer, large-sized biobanks are 
crucial to study the many aspects of this complex disease 
(Watson et al., 2010). SYSUCC biobank currently has 
nearly 15000 tissue samples and over 50000 blood samples 
collected from diagnosed patient for various tumors at dif-
ferent stages, including NPC and esophageal, lung, breast, 
stomach, colorectal, liver, head and neck, gynecologic and 
urinary cancers and lymphomas. In addition with a large 
number of samples, the biobank has been directly connected 
to the Hospital Information System (HIS), allowing an easy 
link between samples and their associated clinical data. 
The rapid development of translational medicine urgently 
needs high-quality bio-specimens which is why SYSUCC 
continually introduce the latest national and international 
advances for standard management and quality control of 
the biobank. For example, the safety of bio-specimens 
stored in ultra-low temperature environment is ensured by a 
temperature management and remote alarm system. A 
management software was developed for sample infor-
mation storage so that each sample can be found easily. 
More importantly, the biobank is equipped with two auto-
mated liquid workstations, an automated blood fractionation 
system and a nucleic extraction purification system. This 
advanced platform contributes to further maintain standard 
operation procedures to keep providing scientists with high 
quality biological samples.  
Upon its establishment, SYSUCC tumor biobank actively 
participated in nearly 500 high level research projects. In 
addition with the genome-wide association study of naso-
pharyngeal carcinoma, the biobank contributed to several 
other large scale projects, such as studies of esophageal 
squamous-cell carcinoma collaborating with researchers 
from Chinese Academy of Medical Sciences and Peking 
Union Medical College, and studies of hepatic carcinoma 
collaborating with researchers from the State Key Labora-
tory of Proteomics.  
In the past, SYSUCC has benefited from collaborations 
with tumor banks of other institutions such as Tianjin Med-
ical University or the Fourth Military Medical University 
but such partnership needs a lot of technical and logistical 
coordination. To facilitate large-scale studies requiring an 
important number of various samples, the creation of na-
tional tumor biobanks in China seems mandatory. The 
American National Cancer Institute set up the first national 
human biobank in 2009, and it was named by Time as one 
of “10 Ideas That Will Change the World” in 2009. An in-
ternet shared network with other tumor biobanks is current-
ly under development which will result in promoting the 
exchange of information among different researchers and 
accelerating the translation of discoveries from bench to 
beside, thus benefiting patients. 
INVESTIGATING CLINICAL ISSUES USING  
BASIC RESEARCH APPROACHES AND  
DISEASE MODELS 
Investigating cancer metastasis 
The major obstacle in improving cancer treatment outcomes 
for many malignancies is metastasis. Metastatic cancer le-
sions are usually difficult to treat not only because they of-
ten involve multiple organs, but also because they are more 
likely to develop resistance to therapies through still-   
unknown mechanisms. Predicting and preventing metastasis 
is crucial in prolonging the survival time of cancer patients. 
One ongoing effort at SYSUCC led by Dr. Chaonan Qian 
is investigating the mechanisms that underlie the motility of 
cancer cells (the “seeds”) as well as the microenvironment 
in the lymph nodes (the “soil”) that favors the growth of 
metastatic cells. The studies on the seeds have been spon-
sored by two grants from the National Natural Science 
Foundation of China, and they focus on the metastatic 
mechanism in NPC, which has the highest metastasis rate 
among head and neck cancers. The sentinel lymph node 
metastasis model developed by Dr. Qian’s group can better 
represent the most frequent type of cancer spread in clinical 
scenarios. They have also isolated high- and low-metastasis 
cellular clones from the NPC cell line CNE-2. The group 
has reported the feasibility of using its metastasis model and 
cellular clones to identify novel molecules promoting tumor 
metastasis (Li et al., 2011a; Li et al., 2011b; Li et. al., 2012). 
So far, three molecules have been characterized as key ele-
ments in promoting NPC metastasis––serglycin, HSP27, 
and interleukin-8 (Li et al., 2011a; Li et al., 2011b; Li et. al., 
2012). The researchers aim to validate at least two more key 
molecules, and all of these molecules could be targets for 
drugs to prevent and inhibit the systemic spread of cancer 
cells. 
In terms of the soil, Dr. Qian and colleagues have found 
that before metastasis, a primary tumor can remodel the 
vasculature of the sentinel lymph node, preparing the mi-
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croenvironment to better support the growth of the meta-
static cancer cells that later arrive (Qian et al., 2006; Qian et 
al., 2007). The group has also shown that the key vascula-
ture component that is remodeled is a special type of blood 
vessel called the high endothelial venule (HEV). It is spec-
ulated that remodeled HEVs not only promote the growth of 
metastatic cancers, but also facilitate the further spread of 
cancer cells to distant organs. This ongoing study aims to 
identify key molecules in the remodeling process of HEVs. 
The overall goal is to inhibit such remodeling and thus the 
spread of cancer cells from the sentinel lymph nodes. 
Postponing cancer onset 
Thanks to the development and application of new technolo-
gies, it is likely that in the near future we will be able to 
predict an individual’s risk of cancer. However, the ability 
to predict risk raises an important clinical issue: how will 
we manage individuals at a high risk of a particular type of 
cancer? 
Recently, Dr. Qian hypothesized that even though people 
harbor a genetic susceptibility to cancer from birth, there 
could be “postponing molecules” in the body that delay the 
onset of cancer (Qian et al., 2010). If this is correct, by am-
plifying the postponing mechanism we should be able to 
delay this onset and provide individuals with a longer can-
cer-free period. To test this novel hypothesis, Dr. Qian and 
his colleagues launched a pilot study using NPC as the dis-
ease model. By applying high-throughput screening of tu-
mor and normal tissues from individuals of different ages, 
they have identified some candidate postponing molecules. 
Unexpectedly, they also found some “accelerator” candi-
dates that appear to be related to early cancer onset. Animal 
models of carcinogenesis could be used to test both sets of 
candidate molecules. This is a typical translational study 
that aims to solve a clinical problem through a series of 
basic research approaches. 
Dissecting tumor vasculature 
Antiangiogenic therapy has provided unexpectedly limited 
survival benefits to cancer patients, and this has necessitated 
an examination of the complexity of tumor angiogenesis 
(Qian et al., 2009; Qin et al., 2012). Dr. Chaonan Qian and 
his colleagues were the first group to differentially analyze 
tumor vasculature in clear-cell renal-cell carcinoma using a 
molecular classification (Yao et al., 2007; Cao et al., 2012). 
An ongoing project of this group is identifying the cellular 
origin of the undifferentiated vessels. This study will open 
the possibility of more specific inhibition of tumor angio-
genesis by targeting different types of tumor vasculature, 
thus enhancing therapeutic outcomes and improving patient 
survival. The strong connections among researchers study-
ing kidney cancer at SYSUCC, the National Cancer Center 
Singapore, and the Cleveland Clinic in the United States led 
to a recently published study (Cao et al., 2012), and this will 
pave the way for additional successful collaborations in the 
future.  
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